CN1043425C - 亚水杨基氨基过渡金属配合物及其制法 - Google Patents
亚水杨基氨基过渡金属配合物及其制法 Download PDFInfo
- Publication number
- CN1043425C CN1043425C CN93117792A CN93117792A CN1043425C CN 1043425 C CN1043425 C CN 1043425C CN 93117792 A CN93117792 A CN 93117792A CN 93117792 A CN93117792 A CN 93117792A CN 1043425 C CN1043425 C CN 1043425C
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrogen
- iii
- group
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims description 23
- 230000008569 process Effects 0.000 title description 2
- 229910001428 transition metal ion Inorganic materials 0.000 claims abstract description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 102
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 50
- -1 benzyloxy methylene Chemical group 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 claims description 21
- 239000001301 oxygen Substances 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- 150000001336 alkenes Chemical class 0.000 claims description 12
- 150000002118 epoxides Chemical class 0.000 claims description 12
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 238000006735 epoxidation reaction Methods 0.000 claims description 5
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 claims description 4
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000013507 mapping Methods 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 claims description 2
- UNVYSECOIMWWKM-UHFFFAOYSA-N 3,6-dihydro-2h-thiopyran Chemical compound C1CC=CCS1 UNVYSECOIMWWKM-UHFFFAOYSA-N 0.000 claims description 2
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 61
- 239000000243 solution Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 239000000203 mixture Substances 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000003756 stirring Methods 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 27
- 238000005406 washing Methods 0.000 description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 17
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 238000010792 warming Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 150000004985 diamines Chemical class 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 150000003527 tetrahydropyrans Chemical class 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 229910052721 tungsten Inorganic materials 0.000 description 8
- 239000004593 Epoxy Substances 0.000 description 7
- 238000011097 chromatography purification Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 6
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000011572 manganese Substances 0.000 description 6
- 150000003053 piperidines Chemical class 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
- 239000005708 Sodium hypochlorite Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical class CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 229940071125 manganese acetate Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 229910052723 transition metal Inorganic materials 0.000 description 4
- RRIQVLZDOZPJTH-UHFFFAOYSA-N 3,5-di-tert-butyl-2-hydroxybenzaldehyde Chemical compound CC(C)(C)C1=CC(C=O)=C(O)C(C(C)(C)C)=C1 RRIQVLZDOZPJTH-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- AMWRITDGCCNYAT-UHFFFAOYSA-L manganese oxide Inorganic materials [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 3
- SMQUZDBALVYZAC-UHFFFAOYSA-N ortho-hydroxybenzaldehyde Natural products OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000006884 silylation reaction Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003624 transition metals Chemical class 0.000 description 3
- 238000007738 vacuum evaporation Methods 0.000 description 3
- AGEBJYJJWHBPJT-UHFFFAOYSA-N $l^{1}-oxidanylsulfonylmethane Chemical compound CS([O])(=O)=O AGEBJYJJWHBPJT-UHFFFAOYSA-N 0.000 description 2
- XWCHAWALBQDAMI-UHFFFAOYSA-N 3-nitro-2,5-dihydrofuran Chemical compound [O-][N+](=O)C1=CCOC1 XWCHAWALBQDAMI-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- LFLBHTZRLVHUQC-UHFFFAOYSA-N butyl methanesulfonate Chemical compound CCCCOS(C)(=O)=O LFLBHTZRLVHUQC-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 2
- 229910001947 lithium oxide Inorganic materials 0.000 description 2
- OPMNROCQHKJDAQ-FKSUSPILSA-N loline Chemical compound C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 2
- 125000005905 mesyloxy group Chemical group 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000000962 organic group Chemical group 0.000 description 2
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical class NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 2
- MXLUQLPDHXJJGL-UHFFFAOYSA-N piperidin-1-yl methanesulfonate Chemical class CS(=O)(=O)ON1CCCCC1 MXLUQLPDHXJJGL-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CSUIJFFOMFLFNH-UHFFFAOYSA-N 2-(trityloxymethyl)oxolane Chemical compound C1CCOC1COC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CSUIJFFOMFLFNH-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- SWPSMRWBGZNFPO-UHFFFAOYSA-N 4-nitrooxolan-3-amine Chemical compound NC1COCC1[N+]([O-])=O SWPSMRWBGZNFPO-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- BDOCSRAQUBFOBF-UHFFFAOYSA-N C(C)(C)(C)C1=C(C(C=NC2OCCC2)=CC(=C1)C(C)(C)C)O Chemical compound C(C)(C)(C)C1=C(C(C=NC2OCCC2)=CC(=C1)C(C)(C)C)O BDOCSRAQUBFOBF-UHFFFAOYSA-N 0.000 description 1
- HXLBHSFCSOPYCV-UHFFFAOYSA-N C[Cl][Na] Chemical compound C[Cl][Na] HXLBHSFCSOPYCV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002521 alkyl halide group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- PEPGQMRXCOOMAP-UHFFFAOYSA-N dioxepane heptane Chemical compound O1OCCCCC1.CCCCCCC PEPGQMRXCOOMAP-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- OPMNROCQHKJDAQ-UHFFFAOYSA-N festucine Natural products C1CC2OC3C(NC)C2N1C3 OPMNROCQHKJDAQ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940059936 lithium bromide Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- FQGYBKCWOANXHP-UHFFFAOYSA-N oxolan-2-yl methanesulfonate Chemical compound CS(=O)(=O)OC1CCCO1 FQGYBKCWOANXHP-UHFFFAOYSA-N 0.000 description 1
- VPSJSRRUXSUNFA-UHFFFAOYSA-N oxolane-3,4-diamine Chemical compound NC1COCC1N VPSJSRRUXSUNFA-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
- B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
- B01J31/2243—At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/02—Synthesis of the oxirane ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/04—Seven-membered rings not condensed with other rings
- C07D321/06—1,3-Dioxepines; Hydrogenated 1,3-dioxepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/70—Oxidation reactions, e.g. epoxidation, (di)hydroxylation, dehydrogenation and analogues
- B01J2231/72—Epoxidation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0238—Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
- B01J2531/0241—Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
- B01J2531/0252—Salen ligands or analogues, e.g. derived from ethylenediamine and salicylaldehyde
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/70—Complexes comprising metals of Group VII (VIIB) as the central metal
- B01J2531/72—Manganese
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
一种通式(Ⅰ)的化合物
其中M是过渡金属离子;
必要时,A是抗衡离子。
Description
本发明涉及一种新催化剂和它们在某些烯烃转化为手性富集环氧化物中的应用。
其中:
M是过渡金属离子,A是阴离子,n是0、1或2。X1或X2中至少一个是选自由硅烷基、芳基、仲烷基和叔烷基组成的组;X3或X4中也至少一个是选自相同的组。Y1、Y2、Y3、Y4、Y5和Y6独立地选自由氢、卤素、烷基、芳基、硅烷基、和带有如烷氧基和卤素的杂原子的烷基组成的组。R1、R2、R3和R4中至少一个选自由H、CH3、C2H5和伯烷基组成的第一组。如果R1选自第一组,则R2和R3选自由芳基、带有杂原子的芳香基、仲烷基和叔烷基组成的第二组。如果R2选自第一组,则R1和R4选自第二组如果R3选自第一组,则R1和R4选自第二组。如果R4选自第一组,则R2和R3选自第二组。
这样的催化剂可以用在前手性烯烃的对映选择环氧化上。
制备了一种结构上完全不同的催化剂,它们出人意料地具有对某些前手性烯烃的对映选择环氧化作用的催化能力。
A必要时是抗衡离子;
r、s和t分别是0-3,以使得r+s+t在1-3的范围内;
Ra、Rb、Rc分别是氢或CH2OR′,这里R′是氢或有机基团;
B和E分别是氧、CH2、NRd,这里Rd是烷基、氢、烷羰基、或芳羰基或SOn,n是0或整数1或2,前提是B和E不能同时是CH2,当B是氧、NRd或SOn时,则r不能为零,当E是氧、NRd或SOn时,则t不能为零;
R1、R2、R3、R4、R5、R6、R7、 R8、R9和R10分别是H、烷基或烷氧基;
合适的过渡金属离子M包括处于适当氧化状态的Mn、Cr、Fe、Ni、Co、Ti、V、Ru和Os。
优选的过渡金属离子M是二价或三价的Mn。
应当理解在某些情况下,如当M是Mn(Ⅱ)时,不需要抗衡离子。
合适的抗衡离子A包括WO91/14694中提到的阴离子。
优选的A是氯。
合适的有机基团R′包括烷基、烷羰基、芳羰基或芳基衍生基团。
特别的R′基团实例包括取代烷基。
R′的一个实例是三苯甲基。
优选的s和t是零,r是1,Ra是氢,B是氧,E是CH2;或者r、s和t都是1,Ra、Rb和Rc是氢,B和E都是氧,或者s为零,r和t都为1,Ra是氢或三苯甲氧基亚甲基,Rc是氢,B是氧,E是-CH2-;或者r、t都是1,s是零,Ra和Rc是氢,B是NRd,这里Rd是苯基羰基,E是CH2。
合适地,R2、R4、R5和R7都代表氢。
合适地,R1、R3、R6和R8分别为C1-6烷基。
特别地,R1和R8是支链烷基,如叔烷基。
R3和R6有利的也是支链烷基。
R1和R6的一优选实例是叔丁基。
R3和R6的特殊实例是叔丁基和甲基。
R2、R4、R5和R7的实例是氢。
当单独使用或作为其它基团的一部分(如烷氧基或烷羰基)时,术语“烷基”包括直链或支链烷基,它们含有1-12个碳原子,合适的是1-6个碳原子,例如,包括甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基。
在这里使用的术语“芳基”包括任意地被多至5个,优选的是多至3个,选自由卤素、烷基、苯基、烷氧基、卤烷基、烷羰基、苯羰基组成的组的基团所取代的苯基和萘基。
一个优选的芳基是取代或非取代苯基。
过渡金属M包括那些具有氧化态为(Ⅱ)或更高的金属。
合适的芳基的取代基包括烷基、卤素和烷氧基。
可选的烷基的取代基包括这里提到过的芳基的取代基,苯基是一特例。
应当理解,带有标记“*”(星号)的碳原子是手性中心,而本发明包括任何单个的对映体和它们的任何混合物。
本发明还提供了一种通式(Ⅰ)化合物的制备方法,它包括形成如下通式(Ⅱ)的化合物的过渡金属的络合物:其中可变的R1至R10、B、E、r、S、t、Ra、Rb和Rc都按通式(Ⅰ)的定义,如有必要,可以是据此分离的任何对映体。
合适地,过渡金属离子的络合物可以在提高的温度下,通过向处于合适溶剂如乙醇或二氯甲烷中的通式(Ⅱ)的化合物添加合适的过渡金属盐,如醋酸锰(Ⅱ)或(Ⅲ),优选的是醋酸锰(Ⅲ),来形成。任选的抗衡离子的置换或互变都可以通过加入含有所需的抗衡离子的碱金属盐如LiCl来进行。
任何对映体的分离都可以通过传统的技术如衍生物的结晶或色谱法来完成。然而应当理解,对映体分离最好是在过渡金属络合物形成之前完成。
本发明进一步提供了一种通式(Ⅱ)的化合物的制备方法,其中包括以任何顺序逐步使通式(Ⅲ)的化合物:其中r、s、t、Ra、Rb和Rc、E、B都如通式(Ⅰ)的定义,而R11、R12单独代表氢或氨保护基团,R11和R12中至少一个是氢,与通式(Ⅳ)的化合物和通式(Ⅴ)的化合物缩合,并在必要时去除任何保护基团R11和R12,
其中R1至R10都按通式(Ⅰ)的定义,此后,按需要分离所需的化合物,包括必要时分离任何对映体。
通式(Ⅱ)的化合物优选的是从通式(Ⅲ)的旋光纯化合物制备,而通式(Ⅲ)的化合物优选的是从其旋光纯起始原料制备。通式(Ⅱ)或(Ⅲ)的化合物对映体的外消旋物或混合物可以应用本领域内的常规技术如衍生物的结晶或色谱法来把它们拆分。
当所需的通式(Ⅱ)的化合物中,R1、R2、R3、R4和R9有一个或多个与R8、R7、R6、R5和R10中的一个或多个分别不相同时,则通式(Ⅲ)化合物可以通过在惰性溶剂如乙醇中加热通式(Ⅲ)的有适当保护的化合物与通式(Ⅳ)或通式(Ⅴ)的化合物(摩尔比1∶1),以任何顺序分步缩合,必要时,可以提纯得到的通式(Ⅵ)或(Ⅶ)的中间化合物:其中可变的R1-R12、r、s、t、Ra、Rb、Rc、E和B都如通式(Ⅲ)、(Ⅳ)和(Ⅴ)中定义,提纯是应用常规的技术如色谱法来去除任何R11或R12的保护基团,当需要时,使用通式(Ⅳ)或(Ⅴ)的化合物重复这些反应。
合适的保护基团R11或R12包括常规的胺保护基团,如苄基、硅烷基或酰基,如苯甲酰基。
代表保护基团的R11或R12的去除可以根据保护基团的性质用本领域内的常规技术来完成。
应当理解。当R1、R2、R3、R4和R5中的每一个与R8、R7、R6、R5和R10的每一个分别相同时,则通式(Ⅳ)和(Ⅴ)的化合物也相同,因此,在惰性溶剂中,在提高的温度下,如在回流条件下,优选地应用其中R11或R12是氢的通式(Ⅲ)的化合物和二摩尔的通式(Ⅳ)或(Ⅴ)的化合物。
通式(Ⅲ)的化合物可以是已知化合物,或者按已知的方法或类似已知的方法或这里描述的类似的方法制备的化合物,如当通式(Ⅲ)的化合物是3,4-二氨基四氢呋喃时,该化合物可按下述方案,例如描述例1和2中所描述的方法来制备。
5R,6R-二氨基-1,3二噁庚环(dioxepane)可按描述例8-13所描述的步骤制备。
3R,4S-二氨基四氢吡喃可以按描述例15-17所描述的步骤来制备。
3R,4R-二氨基-(2 R)(三苯基甲氧基甲基)四氢呋喃可以按描述例21-24所描述的步骤来制备。
(±)反-1-苄氧基-3,4-二氨基哌啶可以按描述例25-27所描述的步骤制备。
通式(Ⅳ)和(Ⅴ)的化合物可以是市场上买到的,或者已知的化合物,或者按已知的方法或类似已知的方法,如G.Casiraghi等人在J.(Them.SOC.Perkin Transaction I.1980 P1862-1865中描述的方法制备的。
通式(Ⅱ)、(Ⅲ)、(Ⅳ)、(Ⅴ)、(Ⅵ)和(Ⅶ)的新化合物构成了本发明的一个方面。
应当理解,术语手性催化剂指对某一种对映体有优势的通式(Ⅰ)的催化剂,因此,它在从前手性烯烃生产环氧化物时可用来形成某种特殊对映体的优势。
应当理解,通式(Ⅰ)的催化剂优选地以手性形式通过使用已拆分的可用传统技术拆分的通式(Ⅲ)的化合物来制备。通式(Ⅲ)的化合物本身可以通过适当的前体来制备,这些前体,如前面论述过的可以用传统技术拆开或可以拆开形式购买到。此外,通式(Ⅱ)的偶合的化合物可以传统技术拆分。
本发明还进一步提供一种在有氧气源和通式(Ⅰ)的手性催化剂存在的条件下对映选择地环氧化前手性烯烃的方法。
合适的前手性烯烃包括含有下述基团作为它们的一部分结构的化合物,环乙烯、5,6-二氢-2H-吡喃、1,2,5,6-四氢吡啶、1,2,3,4-四氢吡啶和5,6-二氢-2H-噻喃。
有利的前手性烯烃包括这些化合物,它们的部分结构形式为如下基团:1,2-二氢萘、2 H-苯并吡喃、1,2-二氢喹啉,1,2-二氢异喹啉和2H-1,2苯并硫吡喃。
这些化合物在钾通道(Channel)活化剂领域内是众所周知的。
优选地,前手性烯烃包括EP-A-0376524中提到的那些烯烃,如那里的通式(ⅩⅣ)的化合物,特别是2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃。
应当理解,本发明特别延伸到用这里所述的方法制备通式(Ⅰ)的化合物特别是其特例用的EP-A-0376524中所有的环氧化物前体。
本发明还特别延伸到再把所有环氧化前体转化成EP-A-0376524中的特殊实例,在这些特殊实例中特别是制备(-)反-3,4-二氢-2,2-二甲基-4-(2-氧代哌啶-1-基)-6-五氟乙基-2H-1-苯并吡喃-3-酚。
合适的氧源包括次氯酸钠。
应当理解,生产EP-A-0376524中描述的化合物的环氧化物前体的3S,4S对映体,只需要通式(Ⅰ)的催化剂的一种对映体,这种对映体再生产EP-A-0376524中描述的通式(Ⅰ)的化合物的3S,4R构型。与之相对应,环氧化物前体的3R,4R对映体用来生产EP-A-0376524中描述的通式(Ⅰ)的化合物的3R,4S构型。
下面用描述例和实施例详细说明本发明。描述例1:(±)2,5-二氢-3-硝基呋喃(D1)
在CH2Cl2(2.2L)中的(±)反3-氯汞基-4-硝基-2,5-二氢呋喃1(38.54g,109.6mmol)和Et3N(11.07g,109.6mmol)的混合物在25℃下搅拌1.25h。加入5%的柠檬酸水溶液(1.1L),继续搅拌5min。通过硅藻土过滤混合物,分离后,有机相用5%柠檬酸水溶液(220ml)洗涤,在Na2SO4上干燥,真空浓缩,在用CHCl3-已烷(1∶1->1∶0)洗脱的硅胶(Merck 9385,300g)上用色谱法提纯残留物,得到冷冻结晶的浅黄色油(D1),5.45g(43.2%)。
δ(CDCl3)4.95(4H,S)和7.10(1H,S)
1.P.Bitha和Y-I Lin,J.Heterocyclic Chem.,1985,25,1035-1036。描述例2:(±)3,4-二氨基四氢呋喃(D2)
用经由Bitha和lin1的方法(用DI)制得的(±)4-氨基-3-硝基四氢呋喃(4.66g,35.3mmol)的EtOH(100ml)的溶液,其中包含有载有10%的钯的碳(2.5g),在Parr摇动设备上,在35psi压力下,在25℃加氢65h。过滤悬浮液,用EtOH(100ml)洗涤固体,收集的滤液在真空下蒸发,得到(±)(D2)的无色油,3.26g(81.5%)。
δ(CDCl3)1.40(4H,b5),3.20(2H,m),3.50(2H,dd)和4.08(2H,dd)。描述例3:
(±)3,4-双(3-权丁基-5-甲基亚水杨基氢基(Sal-icylideamino))四氢呋喃(D3)
将外消旋二胺(D2)(855mg,8.38mmol)和3-权丁基-5-甲基水杨醛(3.22mg,16.76mmol)的EtoH(50ml)溶液加热回流1.5h。真空除去溶剂,在用CHCl3作洗脱剂的硅胶(Merck 9385,300g)上用色谱是纯残留物,得到浅黄针状物(±)(D3),13.5g,(35.8%)
δ(CDCl3)1.42(18H,S),2.25(6H,S),3.95-4.10(2H,M),4.43(2H,g),6.90(2H,d),7.15(2H,d),8.30(2H,S)和13.10(2H,bS)。描述例4:(S,S)反3,4-双(甲磺酰氧基)四氢呋喃(D4)
在THF(75ml)和Et2O(75ml)混合物中的1,4-脱水-L-threitol(2.45g,23.5mmol,从Aldrich Chemical公司购得)溶液在0℃下分步用三乙胺(7.2ml,51.7mmol,2.2eq)和甲磺酰氧(3.82ml,49.35mmol,2.1eq)处理。混合物搅拌4h,再在0℃存放过夜(-16h)。
反应物过滤,用THF(20ml)洗涤固体。收集的滤液在真空下蒸发,再在10%的柠檬酸水溶液(60ml)和EtOAC(150ml)之间分配。干燥(MgSO4)并蒸发有机相,得到无色油(D4),5.82g(95%)。
δ(CDCl3)3.12(6H,S)4.00(2H,dd),4.18(2H,dd)和5.25(2H,dd)。描述例5:(S,S)反3,4-二叠氮基四氢呋喃(D5)
在DMSO(60ml)中的二甲磺酰酯(D4)(5.80g,22.3mmol)和锂的叠氮化物(5.46g,111.5mmol,2.5eq)的混合物在100-110℃下加热40h。冷却至室温后,用水(IL)稀释反应物,并用EtoAC(IL,2×0.75L)萃取。用水(0.5L)和盐水(0.5L)洗涤收集的有机相,在MgSO4上干燥,并真空蒸发,得浅黄色油状的标题化合物,2.18g(61.5%)。
δ(CDCl3)3.75(2H,dd)和3.90-4.05(4H,m)。描述例6:(S,S)反3,4-二氨基四氢呋喃
在0℃下,往无水THF(150ml)中的氢化锂铝(2.05g,54mmol)中,在10min内滴加在THF(50ml)中的二叠氮化合物(D5)(2.08g,13.5mmol)。15min后溶液升温至室温,再搅拌16h。
反应混合物再冷却至0℃,分步用水(2ml),15%的NaOH水溶液(2ml),再用水(6ml)骤冷,再升温至室温、搅拌1h后用硅藻土过滤混合物,用THF(2×150ml)漂洗,收集滤液,真空蒸发,得浅黄色油(D6),1.28g(93%)。
δ(CDCl3)1.30(4H,bS),3.20(2H,dd),3.50(2H,dd)和4.08(2H,dd)。描述例7:(S,S)反3,4-双(3-叔丁基-5-甲基亚水杨基氨基)四氢呋喃(D7)
将(S,S)-二胺(D6)(1.26g,12.35mmol)和3-叔丁基-5-甲基水杨醛(4.74g,24.70mmol)的EtOH(75ml)溶液加热回流3.5h。冷却溶液,真空去除溶剂得黄色油状粗产品(5),5.50g(99%)。
粗产品(4.55g)的试样在硅胶(Merck 9385,含CHCl3的己烷梯度洗脱)得纯的黄色泡沫体(D7),4.39g(95.5%产率)。
δ(CDCl3)1.42(18H,S),2.25(6H,S),3.95-4.10(4H,M),4.33(2H,q),6.90(2H,d),7.15(2H,d),8.30(2H,S)和13.15(2H,bs)。描述例8:
(2R,3R)-1,4-二苯氧基-2,3-二甲磺酰氧基丁烷
向在冰浴中冷却的(2R,3R)-(+)-1,4-二苯氧基-2,3-丁二醇(25.3g,83.7mmol,自Aldrich Chemical公司购得)的二氧甲烷(165ml)溶液中添加甲磺酰氧(13.0ml,167.4mmol),再缓慢添加三乙基胺(23.3ml,167.4mmol),温度不超过5℃。添加完毕后,在有冰浴冷却的情况下搅拌反应物3h。加入水(600ml),分离有机相。再用二氯甲烷(200ml)萃取水相,收集有机相,用水(400ml)和盐水(400ml)洗涤有机相,干燥(MgSO4)蒸去溶剂得浅黄色固体。用乙醚研制得标题化合物(28.2g,74%)的无色结晶,m.p.72-73℃。
1Hn.m.r.(CDDl3):δ3.03(S,6H,2×CH3),3.76(m,4H,2×CH2O),4.48(d,2H,CH2ph),4.57(d,2H,CH2ph),5.00(m,2H,2×CH),7.29-7.39(m,10H,2×ph)。
13Cn,m.r.(CDDl3):δ38.8(2×CH3),68.7(2×CH2),73.7(2×CH2),78.7(2×CH),128.1,128.2,128.6,137.0(2×Ph)。
EI-MS:m/e 459(MH+),367(M+-CH2Ph)。C20H25D8S2计算值:C:52.39,H:5.72%。
实验值:C:52.36,H:5.59%。描述例9:(2R,3R)-二甲磺酰氧基丁烷-1,4-二醇
把(2R,3R)-1,4-二苯氧基-2,3-二甲磺酰氧基丁烷(27.6g,60.3mmol)(D8)溶解在丙酮(500ml)中,添加10%Pd/C(29.9g)的丙酮(300ml)悬浮液,混合物在1atm压力和环境温度下加氢2h。用硅石和硅藻土填充物把混合物过滤三次,蒸去溶剂,得到稻草色的油状标题化合物(14.7g,87%),该油状物存放即固化。
1Hn.m.r.(DMSO-d6):δ3.24(S,6H,2×CH3),3.69(m,4H,2×CH2),4.76(m,2H,2×CH),5.33(t,2H,2×OH)。
13Cn,m.r.(DMSO-d6):δ38.1(2×CH3),59.7(2×CH2),80.3(2×CH)。
EI-MS:m/e279(MH+),261(M+-H2O),183(M+-OMs),165(M+-OMs,H2O)。描述例10:(6R,7R)-二甲磺酰氧基-2,4,9,11-四噁十二烷
将(2R,3R)-二甲磺酰氧基丁-1,4-二醇(14.7g,52.9mmol)(D9)溶解在40℃的二甲氧基甲烷(89.5ml)和二氯甲烷(30ml)中。添加溴化锂(0.91g)和对甲苯磺酸的一水合物(1.01g,5.29mmol),混合物加热回流3h,反应物冷却至室温,再注入饱和碳酸氢钠溶液(200ml),用乙酸乙酯(2×200ml)萃取,干燥(MgSO4)、蒸发得无色油。在硅胶下用柱色谱法纯化,并用含0-1%甲醇的二氯甲烷洗脱,得标题化合物的无色油(8.2g,42%)。
1Hn.m.r.(CDCl):δ3.13S,6H,2×CH3),3.39(S,6H,2×OCH3),3.87(m,4H,2×CH2),4.66(m,4H,2×OCH2O),5.20(m,2H,2×CH)。
13Cn,m.r.(CDCl3):δ38.8(2×SCH3),55.8(2×OCH3)66.1(2×CH2),78.4(2×CH),96.8(2×OCH2O)。
CI-MS:m/e384(MNH4 +)。C10H22O10S2计算值:C:32.78,H:6.05%。
实验值:C:32.22,H:5.62%。描述例11:(5R,6R)-二甲磺酰氧基-1,3-二噁庚环
将(6R,7R)-二甲磺酰氧基-2,4,9,11-四噁十二烷(8.2g,22.4mmol)(D10)和对甲苯磺酸一水合物(0.26g,1.34mmol)的甲苯(165ml)溶液加热回流过夜,蒸去溶剂,棕色残留物用乙醚研制得标题化合物的米白色固体(5.9g,91%)M.P.133-134℃。
1Hn.m.r.(CDCl3):δ3.13(S,6H,2×CH3),3,84(m,2H,CH2),4.06(m,2H,CH2),4.77(S,2H,OCH2O),4.81(m,2H,2×CH)。
13Cn,m.r.(CDCl3):δ38.8(2×CH3),64.1(2×CH2),78.3(2×CH),94.6(OCH2O)。
EI-MS:m/e 291(MNH+),195(M+-OMs)。C7H14O8S2计算值:C:28.96,H:4.86%。
实验值:C:29.22,H:4.61%。描述例12(5R,6R)-二叠氮基-1,3-二噁庚环
在二甲基亚砜(60ml)中的(5R,6R)-二甲磺酰氧基-1,3-二噁庚环D11(5.0g,17.2mmol)和锂的叠氮化合物(4.2g,86mmol)的混合物加热至110-120℃搅拌过夜。冷却混合物,注入水(200ml)中,用乙酸乙酯(2×150ml)萃取。收集有机相,用水(2×150ml)和盐水(150ml)洗涤,干燥(MgSO4),蒸发,得标题化合物的棕色油(2.7g,85%)。
1Hn.m.r.(CDCl3):δ3.49(m,2H,2×CH),3.74(m,2H,2×CH2),3.93(m,2H,CH2),4.73(S,2H,OCH2O)。
13Cn,m.r.(CDCl3):δ64.3(2×CH),64.6(2×CH2),94.3(OCH2O)。EI-MS:m/e185(MH+),157(MH+-N- 2),142(M+-N3)。C5H6N6S2计算值:C:32.61,H:4.38,N:45.63%。
实验值:C:32.33,H:4.67,N:45.38%。描述例13:(5R,6R)-二氨基-1,3-二噁庚环
在0℃和氩气氛中,向氢化锂铝(2.1g,55.3mmol)无水四氢呋喃(70ml)浆液中滴加(5R,6R,)-二叠氮基-1,3-二噁庚环(2.6g,14.1mmol)(D12)的无水四氢呋喃(50ml)溶液。添加过程中,反应温度用冰一盐浴保持在10℃以下。反应完成后,反应混合物升温至室温,再进一步搅拌1.5h。然后再冷却,并用水(2ml),2M NaOH(2ml)和水(4ml)骤冷,用冰一盐浴再把温度维持在10℃以下。骤冷后的反应物再升温至室温,再搅拌2h,然后,用硅藻±和用四氢呋喃洗好的过滤填料过滤,收集滤液,蒸发浓缩,得标题化合物的浅黄色油(1.3g,70%)。
1 Hn.m.r.(CDCl3):δ1.56(6rs,4H,2×NH3),2.62(m,2H,2×CH),3.58(m,2H,CH2),3.77(m,2H,2×CH2),4.72(S,2H,OCH2O)。
13Cn,m.r.(CDCl3):δ57.9(2×CH),67.5(2×CH2),93.8(OCH2O)。C5H12N2O2计算值:C:45.44,H:9.15,N:21.20%。
实验值:C:45.13,H:8.76,N:19.58%。
EI-MS:m/e133(MH+),116(M+-NH2)+,90(M-2NH2)+。描述例14:制备(5R-6R)-二-(3,5-二叔丁基)亚水杨基氨基-1,3-二噁庚环
把(5R,6R)-二氨基-1,3-二噁庚环(1.0g,7.6mmol)(D13)和3,5-二叔丁基水杨醛(3.6g,15.4mmol,2eq)溶解在乙醇(100ml)中,溶液搅拌回流3h。然后使反应混合物冷却,蒸去溶剂,用硅胶柱色谱纯化残流物,并用含4%乙醚的己烷洗脱。得标题化合物的鲜黄色泡沫体(3.5g,82%)。
1 Hn.m.r.(CDCl3):δ1.23(S,18H,6×CH3),1.41(S,18H,6×CH3),3.85(m,2H,CH2),4.07(m,2H,CH2),4.87(S,2H,OCH2O),6.99(d,2H,Ar),7.33(d,2H,Ar),8.33(S,2H,2×CH=N),13.20(drs,2H,2×OH)。
13Cn,m.r.(CDCl3):δ29.4(6×CH3),31.4(6×CH3),34.1(2×CCH3),35.0(2×CCH3),67.7(2×CH),73.8(2×CH2),94.2(OCH2O),117.6,126.4,127.4,136.6,140.3,157.9(Ar),168.4(2×C=N)。C35H52N2O4计算值:C:74.43,H:9.28,N:4.96%。
实验值:C:74.56,H:9.15,N:4.92%。CI-MS:m/e565(MH+)。描述例15:(3R,4R)-二乙酰氧基四氢吡喃(D15)
在大气压和25℃下,氢化含有PtO2(400mg)的3,4-二-O-乙酰基-D-木糖醛(11.16g)的50%乙醇水(400ml)溶液3.5h。用硅藻土过滤悬浮液,再用50%乙醇水溶液(50ml)和水(50ml)洗涤,收集滤液,真空浓缩,得标题化合物的无色油,9.6g(85%)。
δ(CDCl3):1.30-1.50(1H,m),2.10(6H,S),2.10-2.20(1H,m),3.35-3.60(2H,m),3.80-4.00(2H,m)和4.80-5.00(2H,m)。2,《有机化合物词典》,第5版,1982,Chapmar & Hall,London,579和其参考资料。描述例16:(3R,4R)-二甲磺酰氨基四氢吡喃(D16)
在室温下将钠(-50mg)溶解于甲醇100ml)中。向该溶液中添加二酯(D15)(9.56g,47.3mmol)的甲醇(100ml)溶液,混合物搅拌72h。再加入AmberLite IR 120H+树脂(20g),过滤混合物。真空浓缩滤液,得无色油状二醇。把二醇溶解于四氧呋喃(220ml)和二乙醚(220ml)混合液中。加入三乙胺(10.86g,107.5mmol),溶液冷却至0℃。在0℃滴加甲磺酰氟(11.76g,102.7mmol),溶液再搅拌1小时,再在4℃存放16h。过滤悬浮液,用四氢呋喃(2×95ml)和二乙醚(2×180ml)洗涤固体;真空蒸发收集的滤液,残留物在乙酸乙酯(200ml)和10%柠檬酸水溶液(200ml)之间分配。有机相经干燥(MgSO4)、过滤、真空浓缩得标题化合物的无色泡沫体12.07g(93%)。
δ(CDCL3):3.10(6H,S),2.00-2.40(2H,m),3.40-4.20(4H,m),4.55-4.65(1H,m),和4.70-4.85(1H,m)。描述例17:(3R,4S)-二氨基四氨吡喃(D17)
将二甲磺酰酯(D16)(12.07g,44mmol)溶解于二甲亚砜(88ml)中,用锂的叠氮化物(10.8g,220mmol)处理。混合物在100℃下加热40h,冷却至室温,注入水(1.03L)中,用乙酸乙酯萃取(1.03L,2×0.59L)。收集的有机相用水(300ml)和盐水(300ml)洗涤,在MgSO4上干燥,真空浓缩,得棕色油状的粗二叠氮化物3.7g。将这些化合物溶解于四氢呋喃(45ml)中,再滴加到冷的(0℃)氢化锂铝(3.34g,88mmol)的四氢呋喃(220ml)悬浮液中,并维持温度低于10℃。添加完毕后,在0℃搅拌悬浮液0.5h,再升温至室温搅拌16h。
混合物再冷却至0℃,并用含水(3.34ml)的四氢呋喃(5ml)、15%的氢氧化钠水溶液(3.34ml)和水(10ml)骤冷。混合物再升温至室温,搅拌1h,尔后用硅藻土过滤,用四氢呋喃(2×400mml)漂洗。将收集的滤液真空浓缩得无色油状标题的二胺(3),2.62g(51%)。
δ(CDCL3):1.20-1.90(6H,m),2.40-2.50(2H,m),2.90-3.40(2H,m)和3.80-4.00(2H,m)。描述例18:(3R,4S)-双-(3.5-二叔丁基亚水杨基氨基)四氢呲喃,(D18)
向含有二胺(D17)(2.55g,22mmol)的乙醇(220ml)中添加3.5-二叔丁基水杨醛(10.3g,44mmol)。混合物回流加热2h,冷至室温,真空干燥结晶产品,得黄色结晶标题化合物,4.81g(40%)。
δ(CDCl3):1.20(18H,S),1.40(18H,S),1.50-2.20(2H,m),3.50-3.70(4H,m),4.00-4.15(2H,m),7.00(2H,bs),7.35(2h,bs),8.33(1H,S),8.37(1H,S)和13.20(2H,bs)。描述例19:(3R,4S)-双-(3-叔丁基-5-甲基亚水杨基氨基)四氢吡喃(D19)。
将二胺(D17)(0.62g,5.35mmol)和3-叔丁基-5-甲基水杨醛(2.05g,10.7mmol)的乙醇(40ml)溶液加热回流2h。冷却溶液再在4℃存放70h,得黄色沉淀物。过滤,用冷95%乙醇水溶液(5ml)洗涤,真空干燥,得标题化合物,1.22g(49%)。
δ(CDCl3):1.4b(18H,S),1.80-2.20(2H,m),2.20(6H,s),3.40-3.70(4H,m),4.00-4.20(2H,m),6.80(2H,bs),7.05(2H,bs),8.27(1H,S),8.30(1H,S)和13.30(2H,bs)。描述例20:(3S,4S)-双(3,5-二叔丁基亚水杨基氨基)四氢呋喃(D20)
将(S,S)-二胺(D6)(0.96g,9.4mmol)和3,5-二叔丁基水杨醛(4.4g,18.8mmol)的乙醇(90ml)溶液加热回流2h。混合物冷却至0℃,过滤,用冷乙醇洗涤固体物并干燥,得到标题化合物的黄色晶体,3.07g(61%)。δ(CDCl3):1.27(18H,S),1.45(18H,S),3.95-4.10(4H,m),4.30-4.40(2H,m),7.05(2H,d),7.40(2H,d),8.35(2H,S)和13.20(2H,S)。描述例21:(3S,4R)-二羟基-(2R)-(羟甲基)四氢吡喃(D21)
D-己烯糖(16.0g,0.11mmol)的50%乙醇水(500ml)溶液用氧化铂(0.75g)处理,并在室温和大气压下加氢5h。悬浮液用木炭(50g)处理,通过硅藻±(200g)过滤,固体用50%乙醇水溶液(300g)洗涤。收集的滤液在真空下蒸发,在P2O5上干燥,得无色油状标题化合物,16.0g(99%)。
δ(CDDCl3):1.50-1.70(1H,m),1.80-2.20(1H,m),3.00-3.20(2H,m),3.30-3.70(3H,m),3.80-4.00(2H,m)和4.90(3H,bs)。3、《有机化合物词典》,第5版,1982,Chapman和Hall London,2754,和其参考资料。描述例22:(3S,4R)-二羟基-(2R-)-(三苯基甲氧基甲基)四氢吡喃(D22)
用三苯甲基氯(3.31g,11.9mmol)和4-(二甲基氨基)吡啶(50mg)处理三醇(D21)(17.6g,11.9mmol)的吡啶(20ml)溶液。加入二异丙基乙基胺(1.92g,14.8mmol,1.25eq),溶液在室温下搅拌4h。
把混合物注入水(200ml)中,用二乙醚萃取(2×200ml)。收集的有机相用10%柠檬酸水溶液(100ml)和盐水(100ml)洗涤,在MgSO4上干燥,并真空浓缩成油。残留物在硅胶(洗脱剂:含甲醇的氯仿梯度洗脱剂)上用色谱法提纯,得无色泡沫体的标题化合物,3.70g(79.7%)
δ(CDDCl3):1.60-1.80(1H,m),1.90-2.00(1H,m),2.70(2H,bs,D2Oexch),3.25-3.50(5H,m),3.60-3.70(1H,m),3.90-4.00(1H,m)和7.20-7.50(15H,m)。描述例23:(3R,4R)-二甲磺酰氧基-(2R)-(三苯甲氧基甲基)四氢吡喃(D23)
向二乙醚和四氢呋喃(2∶1,150ml)的混合物中的二醇(D22)(3.10g,7.95mmol)中添加三乙胺(1.76g,17.5mmol)。混合物冷至0℃,加入甲磺酰氯(1.91g,16.7mmol)。2h后,过滤悬浮液,真空浓缩滤液,然后再溶解在乙酸乙酯(200ml)中。溶液用10%柠檬酸水溶液(100ml)和盐水(50ml)洗涤。再在MgSO4上干燥。真空去除溶剂,干燥残留物,得(12)无色固体,4.25g,(95%)。
δ(CDDCl3):2.20-2.50(2H,m),2.50(3H,m),3.10(3H,s),3.20-3.30(1H,m),3.40-3.60(3H,m),3.95-4.10(1H,m)4.70-4.80(2H,m)和7.20-7.50(15H,m)。描述例24:(3S,4S)-双(3.5-二叔丁基亚水杨基氨基)-(2R)-三苯甲氧基甲基四氢吡喃(D24)
使二甲亚砜(20ml)中的二甲磺酰酯(D23)(2.85g,5.22mmol)和锂的叠氮化物的混合物在100-110℃下加热24h。冷却溶液,注入水(200ml)中,用乙酸乙酯(2×300ml)萃取。收集的有机相用水(2×300ml)和盐水(300ml)洗涤,在MgSO4上干燥,去除溶剂,得二叠氮中间产物的黄色泡沫体(1.52g)。
在0℃将含1.40g的一份二叠氮化物的四氢呋喃(10ml)加入到含氢化锂铝(470mg),12.4mmol)的四氧呋喃(30ml)悬浮液中,在0℃搅拌1h后,混合物升温至室温,再搅拌16h。悬浮液再冷却至0℃,分别用水(0.5ml)、15%氢氧化钠水溶液(0.5ml)、水(1.5ml)骤冷。升温至室温并搅拌1h后,过滤混合物,用四氢呋喃(2×20ml)洗涤固体,蒸发收集的滤液得粗二胺的泡沫体(1.28g)。
将乙醇(30ml)中的一份二胺(1.18g)和3.5-二叔丁基水杨醛(1.42g,6.08mmol)加热回流4h,再冷至室温,真空去除溶剂,在硅胶上(洗脱剂:含氧仿的已烷梯度洗脱剂)用色谱法提纯残留物得黄色粉未状标题化合物210mg,从(D23)的总收率为8.4%。
δ(CDCl3):1.25(9H,m),1.30-1.60(2H,m),1.32(9H,S),1.40(9H,S),1.50(9H,S),2.40-2.55(1H,S),2.70-2.80(1h,S),3.30-3.60(2H,m),3.90-4.30(3H,m)6.85(1H,bs),7.00-7.35(16H,m),7.38(1H,bs),7.45(1H,bs)8.30(1H,s),8.50(1H,bs),13.25(1H,S)和13.50(1H,S)。描述例25:(±)反-1-苯甲酰基-3,4-双(甲磺酰氧基)哌啶(D25)
将(±)反-1-苯甲酰基哌啶-3,4-二醇(3g,13.6mmol)悬浮在二氧甲烷(70ml)中,加入三乙胺(5.74ml,43mmol)。混合物冷至-10℃,在5min期间加入甲磺酰氯(2.6ml,34mmol)。过15min后,将混合物注入冰水(50ml)中,用15%的柠檬酸水溶液(30ml)洗涤有机相。溶液经在MgSO4上干燥、真空浓缩得泡沫体,5.3g(100%)。
δ(CDCl3):1.95(2H,m),2.30(2H,m),3.15(6H,S),4.70(2H,m),4.85 2H,m)和7.45(5H,m)。4,V.Petrow和0.Stepehnson,J Pharm.Pharmacol,1962,14,360-314。描述例26:(±)反-1-苯甲酰基-3,4-二叠氨基哌啶(D26)
将二甲亚砜(36ml)中的二甲磺酰酯(D25)(5.3mg,14mmol)和锂的叠氮化物(3.4mg,69mmol)的混合物在100℃加热回流18h。冷却后,反应混合物在二氯甲烷(200ml)和水(50ml)之间分配。分离出水相,用二氯甲烷(100ml,50ml)萃取,收集的有机萃取液用水(3×50ml)洗涤,在MgSO4上干燥并真空浓缩。残留物在硅胶(洗脱剂:含甲醇的二氯甲烷梯度洗脱剂)上用色谱法提纯,得标题化合物的无色固体,900mg(24%)。
δ(CDCl3):1.60(2H,m),2.10(2H,m),3.05(2H,m),3.20(2H,m)和7.40(5H,m)。描述例27:(±)反-1-苯甲酰基-3,4-二氨基哌啶(D27)
二叠氨(D26)(450mg,1.7mmol)的乙醇(30ml)溶液用Lind-lar催化剂(5%pd/CaCO3,250mg)处理,在氢气(1atm)中搅拌24h。过滤混合物,真空去除溶剂得油状标题化合物,350mg(94%)。
δ(CDCl3):1.20(1H,m),1.65-1.80(2H,m),2.20(2H,m),2.70(1H,m),3.00(1H,m),3.30(1H,m),4.40(2H,m)和7.40(5H,m)。描述例28(-)反-l-苯甲酰基-3,4-双(3,5-二叔丁基亚水杨基氨基)哌啶(D28)
将胺(D27)(350mg,1.6mmol)和3,5-二叔丁基水杨醛(960g,4.1mmol)的乙醇(40ml)溶液加热回流3h。混合物冷却,过滤,得外消旋双亚胺,625mg(63%)。
将100mg样品用手性高压液相色谱(CHIRALPAKAD,含2%乙醇的己烷洗脱)提纯,得标题化合物的单一对映体,[α]D 25=228°(C=0.13,CHCl3)。
δ(CDCl3):1.20(18H,S),1.45(18H,S),2.00(2H,m),3.25(2H,m),3.45(1H,m),3.55(1H,m),4.35(2H,m),6.95(2H,S),7.40(7H,m),8.30(2H,S)和13.15(2H,bs)。实施例1(±)3,4-双(3-叔丁基-5-甲基亚水杨基氨基)四氢呋喃氯化锰(Ⅲ)(E1)
外消旋配位体(D3)(690mg,1.53mmol)的EtOH(25ml)悬浮液与Mn(OAC)2·4H2O(750mg,3.60mmol)一起加热回流18h。加入LiCl(195mg,4.49mmol)继续回流0.5h。真空去除溶剂,残留物在硅胶(Merck 9385,100g)上用色谱法提纯,用含MeOH的CHCl3梯度洗脱,得标题化合物的棕色粉末(90mg,11%)和未反应的(D3),420mg(61%回收)。实施例2使用(E1)使2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃环氧化为(±)2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E2)
用H2O稀释次氯酸钠水溶液(16.75%W/V,4.44ml,2eg)到12.5ml,加入0.05M NaHPO4(aq)(5ml),将P H值调节至11.3。所得溶液冷却至0℃,把它加入到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(1.39g,5mmol)和催化剂(E1)(45mg,0.1mmol,2mol%)的CH2Cl2(5ml)溶液中。混合物在0℃下搅拌1h,升温至室温再搅拌16h。
加入己烷(50ml)和水(25ml),分离有机相。用己烷(50ml)洗涤水相,收集的有机相在Mg2SO4上干燥,真空浓缩,得浅黄色油,1.42g。
高压液相色谱定量分析显示,包含有1.08g(74%)的所需环氧化物(E2),同时还有痕量(<5%回收率)的原始材料,两种化合物都与真实样品相同(1Hnmr)。实施例3(S,S)反3,4-双(3-叔丁基-5-甲基亚水杨基氨基)四氢呋喃氯化锰(Ⅲ)(E3)方法A(使用醋酸锰(Ⅱ))
使D7(0.95g,2.11mmol)和Mn(OAC)2·4H2O(1.03g,4.22mmol)的EtOH(40ml)溶液加热回流17h。加入氯化锂(268mg,6.33mmol),继续回流0.5h。冷至室温后,真空去除溶剂,在硅胶(meck 9385,梯度洗脱剂为含MeOH的CHCl3)上用色谱法提纯残留物,得棕色粉末(E3)26mg(2.3%)和未反应的(D7)883mg(72%)。方法B(使用醋酸锰(Ⅲ))5.
在CH2Cl2(17ml)和MeOH(17ml)混合物中的(D7)(1.53g,3.4mmol)溶液用Mn(OAC)3·2H2O(0.01g,3.4mmol)处理。混合物加热回流3h,冷却至室温,用氯化锂(0.21g,5.1mmol)处理。搅拌16h后,用真空减少溶剂至约8ml,加入Et2O(70ml),悬浮液搅拌1h。过滤混合物,用Et2O(3×20ml)洗涤固体,真空干燥,得(E3)棕色粉末,1.57g(86%)。
5T.Matsushita和T.Shono,Bull.Chem.Soc.Japan,1981,
54,3743-3748。实施例4使用(E3)使2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃手性环氧化得到(3R,4R)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E4)
用H2O稀释次氯酸钠水溶液(16.75% W/V,8.9ml 20.0mmol)到25ml。加入0.05m NaH2PO4(aq)(10ml),调节PH值至11.3。所得溶液冷却至0℃,加入到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(2.78g,10.0mmol)和催化剂(E3)(0.108g,0.2mmol,2mol%)的二氯甲烷(10ml)溶液中。混合物在0℃下搅拌1h,升温至室温再搅拌20h。
加入己烷(100ml)和水(50ml),分离有机相。用己烷(100ml)洗涤水相,收集的有机相在Mg2SO4上干燥,真空浓缩,得浅黄色油,2.86g。
用高压液相色谱(HPLC)定量分析显示,它包含有2.09g(71%)的所需环氧化物(E4)和少量(约10%)的起始原料,两种化合物都是与真实样品相同,(1H NMR,TLC,HPLC),e.e.=66%,由手性高压液相色谱测定。实施例5制备(R,R)-5,6-双-(3,5-二叔丁基亚水杨基氨基-1,3-二噁庚环)-氧化锰(Ⅲ)
(5R,6R)-二-(3,5-二叔丁基)亚水杨基氨基-1,3-二噁庚环(1.0g,1.77mmol)(D14)和四水合醋酸锰(Ⅱ)(2.l7g,8.87mmol)悬浮在95%乙醇(50ml)中。混合物搅拌回流过夜。加入氯化锂(0.38g,8.96mmol),再继续加热30分钟。冷却反应物,加水(60ml),通过硅藻土过滤。深色沉淀用水洗净,再溶解在二氧甲烷(80ml)中,干燥(MgSO4),蒸去溶剂,得标题化合物的深棕色固体(0.9g,78%)。C35H50N2O4 MnCl计算值:C:64.36.H:7.72.N:4.29%。
实验值:C:64.57,H:7.57,N:4.09%。CI-MS:m/e565(MH-MnCl)+,235(3,5-二叔丁基水杨醛H)+。实施例6用由(R,R)-5,6-双-(3,5-二叔丁基亚水杨基氨基)-1,3-二噁庚环)氯化锰(Ⅲ)催化的次氧酸钠氧化2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃制备(3S,4S)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃
用水把次氯酸钠溶液(11.4% W/V,13.1ml,2eq)稀释至25ml,再加入0.05mol磷酸二氢钠(10ml)。用2mol含水氢氧化钠将溶液的PH值调至11.3,再加到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(2.78g,10mmol)和(R,R)-[1,2-双-(3,5-二叔丁基甲基亚水杨基氨基)-1,3-二噁庚环]-氧化锰(Ⅲ)(0.131g,2mol%)的二氧甲烷(10ml)溶液中,并用冰浴冷却。反应混合物升温至室温,搅拌22h,这时反应基本完成。
用水(50ml)和己烷(100ml)稀释反应物,通过硅藻土过滤,分离有机相,并用另一份己烷(100ml)萃取水相。收集的有机相经干燥(MgSO4)、蒸发得标题化合物的淡黄色固体(2.6g,88%)。用HpLc测定粗产品的手性纯度为e.e=86.0%。粗产品经己烷重结晶得无色晶体m.p.72-73℃。
1Hn.m.r.(CDCl3):δ1.29(S,3H,CH3),1.59(S,3H,CH3),3.53(d,1H,H-3),3.94(d,1H,H-4),6.9(dd,1H,H-8),7.46(dd,1H,H-7),7.57(dd,1H,H-5)。
13Cn,m.r.(CDCl3):δ22.9(CH3),25.5(CH3),50.4(C-3),62.5(C-4),74.1(C-2),113.4(tq,CF3),118.4(C-8),119.1(qt,CF3),120.4(C-4′),121.1(t,C-6),128.1,128.6(2×t,C-5,7),155.7(C-8′)。EI-MS:m/e 294 M+,279(M-CH3)+。C13H11F5O2计算值:C:53.07,H:3.77%。
实验值:C:52.69,H:3.82%。实施例7(3R,4S)-双-(3,5-二叔丁基亚水杨基氨基)-四氢吡喃-氯化锰(Ⅲ)(E7)
配位体(D18)(4.81g,8.8mmol)的二氯甲烷-甲醇(1∶1,88ml)溶液用二水三醋酸锰(2.35g,8.8mmol)处理,并加热回流4h。加入氯化锂(0.56g,13.2mmol),继续加热回流1h。冷却混合物,真空浓缩,残留物用二乙醚(220ml)研制。过滤出固体产品,用二乙醚(2×65ml)洗涤,干燥,得(5)棕色粉末,5.3g(94%)。实施例8用(E7)使2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃手性环氧化得到(3S,4S)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E8)
用水稀释次氯甲钠水溶液(15.24%W/V,9.8ml,20mmol)至25ml 。加入0.05M NaH2PO4(aq)(10ml),调节PH值至11.3。所得溶液冷却至0℃,并加到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(2.78g,10mmol)和催化剂(E7)(127mg,0.2mol%)的二氯甲烷(10ml)溶液中。混合物在0℃搅拌1h,再升温至室温继续搅拌18h。
加入已烷(100ml)和水(50ml),分离有机相。水相用己烷(100ml)洗涤,收集的有机相在MgSO4上干燥,真空浓缩,得黄色固体(2.60g)。
用hplc定量分析显示它含有2.47g(84%)所需环氧化物(E8),与真实样品相同(′Hnmr,tlc,hpLc),用手性hpLc分析ee=88.4%。实施例9(3R,4S)-双-(3-叔丁基-5-甲基亚水杨基氨基)四氢吡喃-氯化锰(Ⅲ)(E.9)
配位体(D19)(928mg,2mmol)的二氯甲烷-甲醇(1∶1,20ml)溶液用二水三醋酸锰(536mg,2mmol)处理,并加热回流3h。混合物冷却至室温,加入氯化锂(128mg,3mmol),搅拌溶液1h。真空浓缩反应混合物,残留物用二乙醚(40ml)研制。过滤出固体产品,用二乙醚(2×15ml)洗涤,真空干燥,得标题化合物的棕色粉未,1.0g(98%)。实施例10使用(E9)使2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃手性环氧化得到(3S,4S)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E8)
用水将次氧酸钠水溶涤(15.24% W/V,9.8ml,20mmol)稀释至25ml,加入0.05M NaH2PO4(aq)(10ml),调节P H至11.3。所得溶液冷至0℃,加到2,2-二甲基-6-五氨乙基-2H-1苯并吡喃(2.78g,10mmol)和催化剂(E9)(111mg,0.2mmol,2mol%)的二氯甲烷(10ml)溶液中。混合物在0℃搅拌1h,再升温至室温,继续搅拌18h。
加入已烷(100ml)和水(50ml),分离有机相。用己烷(100ml)洗涤水相,收集的有机相在MgSO4上干燥,真空浓缩,得(E8)黄色油(2.72g,93%),与真实样品相同(1Hnmr,tlc,hpLc),用手性hpLc分析ee=73%。实施例11(3R,4S)-双-(3,5-二叔丁基亚水杨基氨基)-四氢呋喃-氯化锰(Ⅲ)(E11)
使配位体(D20)(1.07g,2mmol)和二水三醋酸锰(536mg,2mmol)在二氯甲烷和甲醇(1∶1,20ml)中的溶液加热回流6.5h。溶液冷却至室温,加入氯化锂(128mg,3mmol),搅拌混合物16h。真空浓缩反应混合物,用二乙醚(50ml)研制残留物。过滤出固体产品,用二乙醚(2×15ml)洗涤,真空干燥,得标题化合物的棕色粉末,1.12g(89%)。实施例12用(E11)使2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃手性环氧化得到(3S,4R)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E4)
用水将次氯酸钠水溶液(15.24% W/V,9.8ml,20mmol)稀释至25ml,加入0.05M NaH2PO4(aq)(10ml)并调节PH至11.3。所得溶液冷却至0℃,加入到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(2.78g,10mmol)和催化剂(E11)(124.5mg,0.2mmol,2mo1%)的二氯甲烷(10ml)溶液中。混合物在0℃搅拌1h,再升温至室温,搅拌过夜。
加入己烷(100ml)和水(50ml),分离有机相。用己烷(100ml)洗涤水相,收集的有机相经MgSO4干燥,真空浓缩,得黄色油,2.73g。
用hpLc定量分析显示它含有2.47g(84%)所需环氧化物(E4),与真实样品相同(1Hnmr,tlc,hpLc),经手性hpLc分析ee=85.6%。实施例13(3R,4S)-双-(3,5-二叔丁基亚水杨基氨基)-(2R)(三苯甲氧基甲基)四氢吡喃-氯化锰(Ⅲ)(E13)
向配位体(D24)(160mg,195μmol)的二氯甲烷-甲醇(3∶2,5ml)溶液中添加NaOH(0.93ml 0.417摩尔浓度的甲醇,390μmol)和二水三醋酸锰(52.5mg,195μmol)。溶液加热回流3h,加入氧化锂(12.5mg,300μmol),搅拌混合物搅拌15h。
真空去除溶剂,残留物用二乙醚(10ml)研制。过滤出固体产品,用二乙醚(2×2ml)洗涤,干燥后得标题化合物的棕色粉未,136mg(77%)。实施例14用(E13)手性环氧化2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃得到(3S,4S)-2,2-二甲基-3,4-环氧-6-五氟乙基-2H-1-苯并吡喃(E8)
用水将次氯酸钠水溶液(11.4%W/V,2.6ml,4mmol)稀释至5ml,加入0.05M NaH2PO4(aq),调节PH至11.3。所得溶液冷却至0℃,并在0℃加入到2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(560mg,2mmol)和催化剂(E13)(36mg,0.04mmol)的二氯甲烷(2ml)溶液中。反应物在0℃搅拌1h,再在室温下过夜。
加入已烷(20ml)和水(10ml),分离有机相。再用已烷(20ml)萃取水相,收集的有机相经干燥MgSO4、真空去初溶剂得(E8)黄色油,(0.55g)。
hpLc定量分析显示它含有0.496g(84%)所需环氧化物(E8),与真实样品相同(1Hnmr,tlc,hpLc),经手性hpLc分析,ee=84%。实施例15(-)反-1-苯甲酰基-3,4-双-(3,5-二叔丁基亚水杨基氨基)-哌啶-氯化锰(Ⅲ)(E15)
使在二氯甲烷-甲醇(3∶2,5ml)中的(-)配位体(D28)(20mg,0.013mmol)和二水三醋酸锰(10mg,0.037mmol)的混合物加热回流4h。加入氧化锂(1.6mg,0.038mmol),继续回流1h。
真空去除溶剂,残留物在硅胶(洗脱剂:含10%甲醇的二氯甲烷)上用色谱法提纯,得标题化合物的棕色粉末,22mg(97%)。实施例16用(E15)手性环氧化2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃得到(3S,4R)-2,2-二甲基-3,4-环氧-5-五氟乙基-2H-1-苯并吡喃(E4)
2,2-二甲基-6-五氟乙基-2H-1-苯并吡喃(560mg,2mmol)和催化剂(E15)(22mg,0.03mmol)的二氯甲烷(2ml)溶液冷至0℃。加入次氯酸钠水溶液(11.4%W/V,2.6ml,4mmol)和0.05M NaH2PO4(aq)(2mL,PH调至11.3)的混合物。混合物在0℃搅拌1h,升温至室温再搅拌过夜。
混合物用水(10ml)稀释,用己烷(4×20ml)萃取。收集的有机相用水(10ml)洗涤,在NaSO4上干燥,蒸发,得所需环氧化物,492mg(83%)。手性hplc分析显示ee=77%。
Claims (12)
2.根据权利要求1的化合物,其中M是Mn。
3.根据权利要求2的化合物,其中Mn处于氧化状态(Ⅱ)或(Ⅲ)。
4.根据权利要求1的化合物,其中A是氯。
5.根据权利要求1-4中任一权项的化合物,其中s和t是零,r是1,Ra是氢,B是氧,E是CH2;或r、s和t是1,Ra、Rb和Rc是氢,B和E都是氧;或s是零,r和t都是1,Ra是氢或三苯甲氧基亚甲基,Rc是氢,B是氧,E是-CH2-;或者r和t都是1,s是零,Ra和Rc是氢,B是NRd,其中Rd是苯羰基,E是CH2。
6.根据权利要求1-5中任一权项的化合物,其中R1和R8是叔丁基,R3和R6是叔丁基或甲基,R2、R4、R5和R7是氢。
7.一种化合物,它选自:
(±)3,4-双-(3-叔丁基-5-甲基亚水杨基氨基)四氢呋喃氯化锰(Ⅲ);
(S,S)反3,4-双-(3-叔丁基-5-甲基亚水杨基氨基)四氢呋喃氯化锰(Ⅲ);
(R,R)-5,6-双-(3,5-二叔丁基亚水杨基氨基)-1,3-二噁庚环-氯化锰(Ⅲ);
(3R,4S)-双-(3,5-二叔丁基亚水杨基氨基)-四氢吡喃-氯化锰(Ⅲ);
(3R,4S)-双-(3-叔丁基-5-甲基亚水杨基氨基)-四氢吡喃-氯化锰(Ⅲ);
(3S,4S)-双-(3,5-二叔丁基亚水杨基氨基)-四氢呋喃-氯化锰(Ⅲ);
(3R,4S)-双-(3,5-二叔丁基亚水杨基氨基)-(2R)-(三苯甲氧基甲基)四氢吡喃-氯化锰(Ⅲ);
(-)反-1-苯甲酰基-3,4-双-(3,5-二叔丁基亚水杨基氨基)哌啶-氯化锰(Ⅲ)。
8.一种在有氧源和根据权利要求1所定义的通式(Ⅰ)的手性催化剂存在时对映选择地环氧化前手性烯烃的方法。
9.根据权利要求8的方法,其中前手性烯烃包含下组中的一个基团作为其部分结构:环己烯、5,6-二氢-2H-吡喃、1,2,5,6-四氢吡啶、1,2,3,4-四氢吡啶和5,6-二氢-2H-噻喃。
10.根据权利要求8或9的方法,其中前手性烯烃包含作为其部分结构的下组中的一个基团:1,2-二氢萘、2H-苯并吡喃、1,2-二氢喹啉、1,2-二氢异喹啉和2H-1,2-苯并硫吡喃。
11.根据权利要求8-10中任一权项的方法,其中前手性烯烃是2,2二甲基-6-五氟乙基-2H-1-苯并吡喃。
12.根据权利要求11的方法,其中2,2-二甲基-6-五氟乙基-苯并吡喃(3S,4S)-环氧化物产品进一步转化为反-6-五氟乙基-3,4-二氢-2,2-二甲基-4R-(哌啶-2-酮-1-基)-2H-1-苯并吡喃-3S-醇。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929216662A GB9216662D0 (en) | 1992-08-06 | 1992-08-06 | Novel compounds and process |
GB9216662.8 | 1992-08-06 | ||
GB939308968A GB9308968D0 (en) | 1993-04-30 | 1993-04-30 | Novel compounds and process |
GB9308968.8 | 1993-04-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1098415A CN1098415A (zh) | 1995-02-08 |
CN1043425C true CN1043425C (zh) | 1999-05-19 |
Family
ID=26301377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93117792A Expired - Fee Related CN1043425C (zh) | 1992-08-06 | 1993-08-05 | 亚水杨基氨基过渡金属配合物及其制法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5616750A (zh) |
EP (1) | EP0655950B1 (zh) |
JP (1) | JP3322877B2 (zh) |
KR (1) | KR100292137B1 (zh) |
CN (1) | CN1043425C (zh) |
AT (1) | ATE144441T1 (zh) |
AU (1) | AU672995B2 (zh) |
CA (1) | CA2141790A1 (zh) |
DE (1) | DE69305645T2 (zh) |
DK (1) | DK0655950T3 (zh) |
ES (1) | ES2093523T3 (zh) |
GR (1) | GR3021743T3 (zh) |
HK (1) | HK1006289A1 (zh) |
MX (1) | MX9304761A (zh) |
NZ (1) | NZ254917A (zh) |
TW (1) | TW418210B (zh) |
WO (1) | WO1994003271A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3801626B2 (ja) * | 1994-02-04 | 2006-07-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | プロキラルなオレフィンのエポキシ化法およびそのエポキシ化に用いる触媒ならびにその触媒を調製するための中間体 |
KR19980702645A (ko) * | 1995-03-08 | 1998-08-05 | 알베르투스 빌헬무스 요아네스 쩨스트라텐 | 촉매 조성물내 브리지된 비스-아미도 4족 금속 화합물 |
US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
US20030017941A1 (en) | 1997-03-07 | 2003-01-23 | The Procter & Gamble Company | Catalysts and methods for catalytic oxidation |
ZA981883B (en) * | 1997-03-07 | 1998-09-01 | Univ Kansas | Catalysts and methods for catalytic oxidation |
EP0977828B1 (en) | 1997-03-07 | 2005-05-11 | The Procter & Gamble Company | Bleach compositions |
TWI246520B (en) | 1997-04-25 | 2006-01-01 | Mitsui Chemicals Inc | Processes for olefin polymerization |
US5981424A (en) * | 1997-07-31 | 1999-11-09 | Sunoco, Inc. (R&M) | Catalysts for hydroxylation and ammination of aromatics using molecular oxygen as the terminal oxidant without coreductant |
NL1007776C2 (nl) * | 1997-12-12 | 1999-06-15 | Dsm Nv | Katalysator voor de bereiding van chirale producten in optisch actieve vorm. |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
US6656450B2 (en) | 2000-07-17 | 2003-12-02 | California Institute Of Technology, Inc. | Macrocyclic magnetic resonance imaging contrast agents |
CN1186125C (zh) * | 2002-06-18 | 2005-01-26 | 中国科学院成都有机化学研究所 | 用于氧化偶联萘酚的手性催化剂 |
FR2875500A1 (fr) * | 2004-09-21 | 2006-03-24 | Centre Nat Rech Scient | Complexe chiraux macrocycliques utilisables comme catalyseurs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014694A1 (en) * | 1990-03-21 | 1991-10-03 | Research Corporation Technologies, Inc. | Chiral catalysts and epoxidation reactions catalyzed thereby |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0023075A1 (en) * | 1979-07-13 | 1981-01-28 | Imperial Chemical Industries Plc | Process for the preparation of cyclopropane carboxylic acid esters |
US5250285A (en) * | 1985-05-08 | 1993-10-05 | The General Hospital Corporation | Hydroxy-aryl metal chelates for diagnostic NMR imaging |
FR2588265B3 (fr) * | 1985-10-04 | 1988-01-15 | Inst Francais Du Petrole | Procede d'adoucissement d'une charge d'hydrocarbures contenant des produits soufres |
JPS6490150A (en) * | 1987-09-30 | 1989-04-06 | Soda Aromatic | Production of 3,5,5-trimethylcyclohex-2-ene-1,4-dione |
EP0669339B1 (en) * | 1994-02-23 | 2001-05-23 | Nissan Chemical Industries Ltd. | Asymmetric epoxidation process using optically active manganese complexes |
-
1993
- 1993-08-05 CN CN93117792A patent/CN1043425C/zh not_active Expired - Fee Related
- 1993-08-05 DK DK94906734.2T patent/DK0655950T3/da active
- 1993-08-05 DE DE69305645T patent/DE69305645T2/de not_active Expired - Lifetime
- 1993-08-05 AU AU47223/93A patent/AU672995B2/en not_active Ceased
- 1993-08-05 CA CA002141790A patent/CA2141790A1/en not_active Abandoned
- 1993-08-05 ES ES94906734T patent/ES2093523T3/es not_active Expired - Lifetime
- 1993-08-05 AT AT94906734T patent/ATE144441T1/de not_active IP Right Cessation
- 1993-08-05 EP EP94906734A patent/EP0655950B1/en not_active Expired - Lifetime
- 1993-08-05 MX MX9304761A patent/MX9304761A/es not_active IP Right Cessation
- 1993-08-05 WO PCT/GB1993/001666 patent/WO1994003271A1/en active IP Right Grant
- 1993-08-05 JP JP50513994A patent/JP3322877B2/ja not_active Expired - Lifetime
- 1993-08-05 KR KR1019950700430A patent/KR100292137B1/ko not_active IP Right Cessation
- 1993-08-05 NZ NZ254917A patent/NZ254917A/en unknown
- 1993-08-05 US US08/129,162 patent/US5616750A/en not_active Expired - Lifetime
- 1993-08-07 TW TW082106340A patent/TW418210B/zh not_active IP Right Cessation
-
1996
- 1996-11-20 GR GR960403145T patent/GR3021743T3/el unknown
-
1998
- 1998-06-16 HK HK98105431A patent/HK1006289A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991014694A1 (en) * | 1990-03-21 | 1991-10-03 | Research Corporation Technologies, Inc. | Chiral catalysts and epoxidation reactions catalyzed thereby |
Non-Patent Citations (3)
Title |
---|
J.AM.CHEM.SOC 1986,108,2309-2320 1986.1.1 EPOLDATION of olefis witllt catioic(sale) Mn complex * |
J.AM.CHEM.SOC 1986,108,2309-2320 1986.1.1 EPOLDATION of olefis witllt catioic(sale) Mn complex;J.AM.CHEM.SOC 1990,112,2801-2803 1990.3.1 W.Zang Enanllcosedtive epoxydation of uivfuction * |
J.AM.CHEM.SOC 1990,112,2801-2803 1990.3.1 W.Zang Enanllcosedtive epoxydation of uivfuction * |
Also Published As
Publication number | Publication date |
---|---|
JP3322877B2 (ja) | 2002-09-09 |
GR3021743T3 (en) | 1997-02-28 |
US5616750A (en) | 1997-04-01 |
HK1006289A1 (en) | 1999-02-19 |
AU4722393A (en) | 1994-03-03 |
WO1994003271A1 (en) | 1994-02-17 |
CA2141790A1 (en) | 1994-02-17 |
DE69305645T2 (de) | 1997-06-05 |
TW418210B (en) | 2001-01-11 |
AU672995B2 (en) | 1996-10-24 |
EP0655950A1 (en) | 1995-06-07 |
ATE144441T1 (de) | 1996-11-15 |
CN1098415A (zh) | 1995-02-08 |
DK0655950T3 (da) | 1996-11-18 |
ES2093523T3 (es) | 1996-12-16 |
DE69305645D1 (de) | 1996-11-28 |
KR950702872A (ko) | 1995-08-23 |
JPH08500099A (ja) | 1996-01-09 |
NZ254917A (en) | 1996-11-26 |
MX9304761A (es) | 1994-05-31 |
EP0655950B1 (en) | 1996-10-23 |
KR100292137B1 (ko) | 2001-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1043425C (zh) | 亚水杨基氨基过渡金属配合物及其制法 | |
KR101395377B1 (ko) | Hiv 단백질 분해 효소 억제제 및 그를 포함하는 약학 조성물 | |
CN1430599A (zh) | 苯基甘氨酸衍生物 | |
CN1553915A (zh) | 制备六氢-呋喃并[2,3-b]呋喃-3-醇的方法 | |
CN1039910C (zh) | 雪花胺衍生物、其制备方法及其作为药物的用途 | |
CN1111245A (zh) | 雪花胺衍生物、其制备方法及其作为药物的用途 | |
CN1239493C (zh) | 3,6-二烷基-5,6-二氢-4-羟基-吡喃-2-酮的合成方法 | |
CN105392772B (zh) | 奥格列汀的关键中间体的制备方法 | |
JP2021100953A (ja) | ピリミジニルシクロペンタン化合物の調製方法 | |
CN1040440C (zh) | 去氢环黄皮酰胺衍生物的制备方法 | |
CN100349867C (zh) | 制备r,r(或s,s)构型的格隆铵-立体异构体的方法 | |
CN1065866A (zh) | 酚2-哌啶子基-1-链烷醇的前体酯 | |
US8912345B2 (en) | Method for preparing optically pure (−)-clausenamide compound | |
CN1255498A (zh) | 生长激素促分泌剂的制备方法和中间体 | |
CN1103402A (zh) | 取代的吡咯类化合物 | |
JP2016164143A (ja) | Hcvの大環状プロテアーゼ阻害剤の製造のための方法及び中間体 | |
CN1860115A (zh) | 制备手性丙酸衍生物的方法 | |
CN1078720A (zh) | 丁二烯衍生物及其制备方法 | |
CN1868996A (zh) | 纯化普伐他汀的方法 | |
JP2004517891A (ja) | ディスコデルモリドおよびディスコデルモリド類似体製造用中間体の製造方法 | |
CN1019486B (zh) | r-丁内酰胺的制备方法 | |
WO2006123767A1 (ja) | 不斉四置換炭素原子含有化合物の製法 | |
WO2020235665A1 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
Yamauchi et al. | Syntheses of (+)-and (−)-Dihydropinidine and (+)-and (−)-Epidihydropinidine by Using Yeast Reduction of Methyl (2-oxocyclohexyl) acetate | |
KR100933172B1 (ko) | 아토르바스타틴 칼슘염의 개선된 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |